# ART Modulation of Viral Pathogenesis

> **NIH NIH R01** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2021 · $369,313

## Abstract

Project Summary Abstract
The majority of human immune deficiency virus 1 infected patients in the US are on long-term (10+ years)
combination antiretroviral therapy (cART). While cART suppresses HIV replication to below 50 copies/ml, not
much is known about the long-term effect of cART on Kaposi sarcoma associated herpesvirus (KSHV) oral
transmission, oral and systemic KS disease or the latent KSHV reservoir. We propose to investigate the impact
that different cART components have on KSHV and KS disease with the long-term aim to interrupt oral KSHV
transmission and cure the virus from persons living with HIV/AIDS. Specifically, we will focus on modulating the
reactivation of KSHV and how cART drugs affect KSHV exosomes/ extracellular vesicles. This is a competitive
renewal application in response to PA-16-426/ "High" or "Medium" Priority AIDS Research on Non-AIDS-defining
or AIDS-defining Cancers (R01).

## Key facts

- **NIH application ID:** 10137212
- **Project number:** 5R01DE018304-13
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** Dirk P Dittmer
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $369,313
- **Award type:** 5
- **Project period:** 2007-05-15 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10137212

## Citation

> US National Institutes of Health, RePORTER application 10137212, ART Modulation of Viral Pathogenesis (5R01DE018304-13). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10137212. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*